Covid-19: WHO-sponsored preliminary review indicates Ivermectin effectiveness – Swiss Policy Research
Published: December 31, 2020 (upd.)
Share on: Twitter / Facebook
WHO-sponsored review of ivermectin trials indicates 83% reduction in covid mortality.
Dr Andrew Hill of the Department of Pharmacology at the University of Liverpool (UK) is currently performing a WHO-sponsored review and meta-analysis of randomized controlled trials of ivermectin against covid. In the following 12-minute video, Dr Hill is presenting his preliminary results, which indicate a highly significant 83% reduction in covid mortality (95% CI 65%-92%).
This result is based on in-hospital trials, so it does not yet take into account early ambulatory and prophylactic treatment. The authors of the review intend to include three more trials, due to be published sometime in January, before providing a final conclusion. At the end of his presentation, Dr Hill describes low-cost ivermectin as a potentially “transformative treatment” against covid.
Update January 20: The final analysis has been published as a preprint on Research Square. It found a 75% reduction in covid mortality and will be continually updated with future trial results.
Additional material
- Studies overview: Overview of all covid-19 ivermectin studies (IVMMETA)
- Covid-19 treatment protocol: Front Line Covid-19 Critical Care Alliance (FLCCC)
- Mode of action: Ivermectin highly effective in inhibiting coronavirus replication (NCB)
Where to buy Ivermectin
If not available locally, Ivermectin can be bought from certified pharmaceutical exporters on Indiamart, but some countries may not allow its importation. Patients are asked to consult a doctor.